top of page
Browse by category
Search


Qaelon Medical establishes Data Advisory Board to detect, prevent and predict surgical leaks
Qaelon Medical has announced the formation of its Data Advisory Board (DAB) dedicated exclusively to data-driven detection, prevention...


New drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass
A new potential drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass, according to a...


Only one in 12 remain on a GLP-1 drug for obesity at three years
Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to...


Increase in number of cases of acute and chronic pancreatitis linked to GLP-1 medicines
Data from the UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has revealed that since...


Nitinotes to initiate US trial of the EndoZip System for endoscopic sleeve gastroplasty
Nitinotes has received approval from the FDA to initiate a pivotal clinical trial of the EndoZip System for endoscopic sleeve...


Robotic outcomes comparable with laparoscopic bariatric surgery
The number of robotic MBS procedures in Australia has risen over the years but the proportion of surgeons performing them remain...


Liraglutide found to reduce the frequency of migraines
Liraglutide has been found to lower brain fluid pressure cutting monthly migraine days by more than half, according to a new study,...


Study identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome
Researchers from the George Washington University have uncovered evidence in an animal study that shows setmelanotide, an FDA-approved...


Weighted vests do not prevent bone loss in older adults undergoing intentional weight loss
A randomised clinical trial, led by a team of researchers from Wake Forest University School of Medicine and Wake Forest University, did...


REDEFINE 1 trial: CagriSema results in 22.7% mean weight reduction in adults with overweight or obesity
Outcomes from Novo Nordisk's phase 3 REDEFINE 1 trial - evaluating the efficacy and safety of investigational CagriSema plus lifestyle...
Browse by tag






bottom of page

